Review article: experimental therapies in autoimmune hepatitis

Neil Halliday1,2 | Jessica Katharine Dyson3,4 | Douglas Thorburn1,2 | Ansgar W. Lohse5 | Michael A. Heneghan6

1Institute of Liver and Digestive Health, University College London, London, UK
2The Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK
3Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK
4Hepatology Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
5Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6Institute of Liver Studies, King’s College Hospital, London, UK

Correspondence
Neil Halliday, Institute of Liver and Digestive Health, University College London, Royal Free Campus, Rowland Hill Street, London, UK.
Email: neilhalliday@doctors.org.uk

Summary

Background: Current therapeutic options for autoimmune hepatitis (AIH) are limited by adverse events associated with corticosteroids and thiopurines and the limited evidence base for second- and third-line treatment options. Furthermore, current treatment approaches require long-term exposure of patients to pharmacological agents. There have been significant advances in the understanding of the mechanisms underpinning autoimmunity and an expansion in the available therapeutic agents for suppressing autoimmune responses or potentially restoring self-tolerance.

Aim: To review the mechanisms and evidence for experimental therapies that are being actively explored in the management of AIH.

Methods: We have reviewed the literature relating to a range of novel therapeutic immunomodulatory treatment strategies and drugs.

Results: Drugs which block B cell-activating factor of the tumour necrosis factor family (BAFF) and tumour necrosis factor α are currently in clinical trials for the treatment of AIH. Experimental therapies and technologies to increase immune tolerance, such as pre-implantation factor and regulatory T cell therapies, are undergoing development for application in autoimmune disorders. There is also evidence for targeting inflammatory pathways to control other autoimmune conditions, such as blockade of IL1 and IL6 and Janus-associated kinase (JAK) inhibitors.

Conclusions: With the range of tools available to clinicians and patients increasing, it is likely that the therapeutic landscape of AIH will change over the coming years and treatment approaches offering lower corticosteroid use and aiming to restore immune self-tolerance should be sought.


1 INTRODUCTION

Autoimmune hepatitis (AIH) manifests as an inflammatory disorder of the liver parenchyma and is associated with hypergammaglobulinaemia, circulating autoantibodies, specific HLA-DR alleles and characteristic histological changes.\(^3\)\(^-\)\(^5\) AIH may result in a chronic, fluctuating hepatitis, potentially leading to progressive fibrosis, cirrhosis and chronic liver failure. It may also present as an acute severe hepatitis with the potential for acute liver failure.\(^6\) Defined as a rare disease, with a prevalence of 11.6-34.5 per 100 000 population,\(^7\)\(^-\)\(^9\) the condition accounts for 5% of elective liver transplants in Europe\(^1\)\(^0\) and is an indication for liver transplantation in the setting of acute liver failure.\(^6\)\(^,\)\(^1\)\(^1\)

Despite a long established evidence base for first-line therapy consisting of azathioprine and corticosteroids, and broadly agreed second-line therapy with mycophenolate mofetil (Table 1), 15%-20% of patients are intolerant of, nonresponsive to or have a contraindication to taking these therapies.\(^1\)\(^2\) Both active disease and side effects from the currently available treatments are now recognised to have a significant negative impact on quality of life for patients, with corticosteroids being associated with the greatest reduction in health utility.\(^1\)\(^3\)\(^-\)\(^1\)\(^5\) There is active interest in developing novel therapies that may reduce disease activity, enhance immune tolerance and avoid the adverse consequences associated with corticosteroid use in AIH.

Advances in our understanding of the mechanisms underpinning autoimmune responses and the recognition that similar genetic influences and effector mechanisms contribute to a wide range of single organ and systemic autoimmune diseases\(^1\)\(^6\)\(^-\)\(^1\)\(^8\) have resulted in a range of novel agents for controlling autoimmune responses. Due to the overlap in mechanism between different autoimmune disorders, it is plausible that treatments effective in one autoimmune disorder may be efficacious in AIH and hence should be considered for clinical trials in AIH.

In this review, we summarise the rationale and background to experimental therapies that have entered clinical trials in AIH, such as B cell-activating factor of the tumour necrosis factor family (BAFF) targeting therapies, anti-tumour necrosis factor (anti-TNF) therapy, pre-implantation factor and strategies that improve regulatory T cell function. We also discuss the potential for targeting proinflammatory cytokines IL1 and IL6 and Janus Kinase (JAK) inhibitors, which have received attention recently in a range of autoimmune disorders.

| TABLE 1 | Current treatment options for autoimmune hepatitis |
|---------------------------------|-----------------|------------------|
| **Drug class** | **Typical medications** | **Role in AIH** |
| **First line** | | |
| Corticosteroids | Prednisolone | Strong evidence base for induction and maintenance of remission. Significant side effect burden. |
| | Hydrocortisone | |
| | Budesonide | |
| Thiopurines | Azathioprine | Strong evidence base for induction and maintenance of remission. |
| | Mercaptopurine | No formal evidence of efficacy, small case series only. Possibly equivalent to azathioprine |
| | Tioguanine | |
| **Second line** | Mycophenolate mofetil | Used for maintenance of remission. Evidence of efficacy based on case series. RCT vs azathioprine ongoing |
| **Third line** | Tacrolimus | Probably effective in setting of intolerance and nonresponse to first- and second-line agents. Evidence from multiple case series. Ciclosporin used in paediatrics |
| Calcineurin inhibitors | Ciclosporin A | |
| Anti-CD20 | Rituximab or anti-CD20 biosimilars | Probably effective in maintenance of remission, evidence from small case series |

**Experimental therapies**

| **Current trials** | Anti-BAFF | Ianalumab | Multicentre, randomised placebo-controlled phase II/III trial ongoing |
| | Anti-TNF | Infliximab | Small case series suggesting efficacy in rescue therapy in difficult-to-treat patients |
| **Possible future trials** | Novel peptides | Pre-implantation factor | Phase I safety study in patients with AIH complete. Experimental only |
| | Treg therapies | Adoptive Treg transfer | Early phase trials completed in other autoimmune conditions and transplantation. Feasible in AIH |
| | Low-dose IL2 | Case reports of short-term efficacy in a few patients |
| | Treg stimulators | Not tested in AIH, in early phase trials in other autoimmune conditions |
| **No trials currently planned** | IL1 blockade | Canakinumab | No reports of use in AIH, ongoing trials in acute alcoholic hepatitis |
| | IL6 blockade | Tocilizumab | No reports of use in AIH |
| | JAK inhibitors | Filgotinib, Ruxolitinib | No reports of use in AIH, increasing use in other autoimmune conditions |

Abbreviations: BAFF, B cell-activating factor of the tumour necrosis factor family; IL, interleukin; JAK, Janus kinase; RCT, randomised controlled trial; TNF, tumour necrosis factor.
Finally, we discuss the potential approach for investigative studies that may bring novel agents into practice in AIH. Any novel therapies should only be offered in specialist centres with an interest in AIH, experience in clinical trials and within formal prospective clinical trials wherever possible.

Firstly, we will briefly review the current understanding of the immunopathogenesis of AIH to illustrate the context for possible treatment approaches.

1.1 | Current treatment approaches

The current treatment paradigm in AIH is induction of remission with corticosteroids (typically prednisolone 0.5-1 mg/kg) and then maintenance of remission with azathioprine started at 1 mg/kg while corticosteroids are weaned, with the aim of azathioprine monotherapy in the long term (Table 1). Remission is defined as normalisation of serum transaminases and IgG with minimal histological activity on biopsy (although this is rarely performed to confirm remission). Some patients require long-term low-dose corticosteroids in addition to azathioprine to maintain remission. Inadequate response to azathioprine should prompt consideration of dose optimisation to therapeutic drug monitoring for toxicity and assessment of treatment concordance.

The majority of patients respond to treatment with corticosteroids and azathioprine, with remission rates of 44%-100% observed, although these studies often used high doses of corticosteroids for maintenance. Despite the potential efficacy of this treatment approach, failure to achieve remission is common; a large, real-world assessment of current treatment in >1200 patients in the UK demonstrated that biochemical remission was achieved in <60% of patients. Furthermore, among patients in complete biochemical remission, relapse rates of >50% and significant corticosteroid side effects in 30%-40% of patients are observed, demonstrating that despite current treatment approaches being potentially effective, a significant proportion of patients will continue to experience disease activity or treatment toxicity.

Intolerance, inadequate response or contraindication to corticosteroid and azathioprine treatment, including a requirement for high-dose corticosteroids (>10 mg prednisolone per day) to maintain remission, should prompt consideration of second-line therapies. Mycophenolate mofetil is typically offered as a second-line agent for those patients intolerant to azathioprine (Table 1) and although there is no high-quality trial evidence to support this approach, there are extensive case series data suggesting efficacy. The efficacy of mycophenolate mofetil as a second-line drug for those patients with insufficient response to standard therapy is questionable, and optimising first-line therapy by checking adherence and drug levels needs to be considered. Third-line therapies, including tacrolimus, infliximab and anti-CD20 monoclonal antibodies (rituximab), may be employed (Table 1) depending upon local availability, monitoring and clinician and patient choice.

Despite these range of treatment approaches, there remain up to 20% of patients who do not respond adequately to treatment or experience significant side effects. There is, therefore, a need for novel agents to expand the range of options for patients with AIH and their treating clinicians.

2 | IMMUNOPATHOGENESIS OF AIH

The immunopathogenesis of AIH is underpinned by the loss of self-tolerance and resultant immune-mediated damage of the liver. An increased risk of AIH is associated with a range of genetic variants; variants at human leucocyte antigen (HLA)-DRB1, -DRB3 and -DRB4 loci have most commonly been identified. Non-HLA associations, including immune regulation or signalling pathways such as cytokine pathways, including TNFα and transforming growth factor-β, among others, have been described. A range of environmental factors have been suggested to trigger autoreactive immune responses resulting in the loss of self-tolerance in susceptible individuals, including drugs and viral infections.

Loss of self-tolerance results from autoreactive CD8 and CD4 T cells and B cells recognising autoantigens presented on class I and class II HLA leading to their activation and proliferation. B cells mature into plasma cells and secrete antibodies capable of recognising self-antigens, cytotoxic CD8 T cells directly damage tissues and CD4 T cells secrete a range of proinflammatory cytokines resulting in the recruitment and activation of other immune effectors, including mucosal-associated invariant T cells, natural killer cells and natural killer T cells, all of which may be important in AIH.

Adaptive immune responses are typically constrained by a range of mechanisms: restriction of antigen presentation, control of (co-) stimulatory signals, regulatory cytokines and specific cell populations, termed regulatory cells, which suppress the proliferation and activation of adaptive immune effectors. Regulatory CD4 T cells (Tregs) and regulatory B cells (Bregs) control T cell responses and are important in the maintenance of self-tolerance. Impairment of Treg function and frequency has been recognised as a potential factor in AIH and similarly Breg have been recognised to be important in a range of autoimmune diseases.

Immune cell activation in the liver results in changes in the cytokine profile and alteration of the recruitment and activation of other immune cell subsets. CD4 T cells typically differentiate into subtypes with specific cytokine profiles: Th1 cytokine-secreting cells secrete interferon-γ (IFNγ) that induces upregulation of class I and II HLA expression, resulting in increased antigen presentation and also stimulates CD8 T cells and macrophages resulting in IL1 and TNFα release. Th2 T cells produce IL4, IL10 and IL13 resulting in B cell maturation. The presence of IL6 prevents the differentiation of Treg and results in the generation of Th17 cells, which have been implicated in AIH. Th17 cells secrete IL17 which in turn induces release of IL6 by hepatocytes; this may enable a feedback loop increasing pathogenic...
Th17 cell differentiation. Furthermore, the inflamed liver microenvironment appears to suppress Treg function directly. The inflammatory response in the liver results in an inflammatory infiltrate consisting of CD4 and CD8 T cells, B cells, plasma cells, natural killer cells, monocytes, macrophages and eosinophils.

The pathology observed in AIH is a result of the activation of a network of cells, signalling pathways, regulatory mechanisms and cytokines from both the innate and adaptive limbs of the immune system. This offers a range of therapeutic targets where the inflammatory process in AIH may be interrupted and potentially even restore immune tolerance. Therefore, therapies with efficacy in other autoimmune diseases that target these pathways may be of use in AIH.

3 | NOVEL THERAPIES UNDERGOING CLINICAL ASSESSMENT IN AIH

3.1 | B cell-activating factor of the tumour necrosis factor family (BAFF) targeting therapies

The association of hypergammaglobulinaemia and circulating autoantibodies with AIH and other autoimmune disorders suggests that B cell activity may be an important contributor to autoimmunity. Therefore, therapeutic targeting of B cells to reduce the production of potentially pathogenic antibodies and B cell antigen-presenting activity in autoimmunity is an attractive proposition.

Rituximab, an anti-CD20 monoclonal antibody, is an established therapy in autoimmune disorders and may have a role in the treatment of AIH. A recent retrospective report collating outcomes for 22 patients in Northern Europe and Canada demonstrated an improvement in liver biochemistry and reduction in corticosteroid doses following two 1000 mg doses of rituximab given 2 weeks apart (five patients received repeat dosing), suggesting that therapeutic targeting of B cells might be a useful approach in AIH.

Recently, a range of agents targeting BAFF have been developed. BAFF is a 285 amino acid protein produced by myeloid cells that may be membrane bound or cleaved by proteases producing a soluble cytokine. BAFF transmits a B cell survival signal important for B cell development (Figure 1) and interacts with three receptors on B cells, binding either as multimers or heteromers with a related protein called A proliferation-inducing ligand (APRIL).

While the importance and pathogenic role of B cells and autoantibodies in AIH are debated, several pieces of evidence support the therapeutic targeting of B cells. Soluble BAFF levels are elevated in AIH and correlate with serum transaminase, immunoglobulin G and bilirubin levels, and BAFF levels fall with corticosteroid treatment. Similarly, BAFF levels are elevated in a range of autoimmune disorders, including primary biliary cholangitis, systemic lupus erythematosus, rheumatoid arthritis, coeliac disease, Sjögren’s syndrome, systemic sclerosis, myasthenia gravis and correlate with autoantibody titres. BAFF levels are also elevated in chronic inflammation in the settings of chronic infection, malignancy and allergy. Additionally, liver-infiltrating B cells are seen in acute AIH, more so than when compared to other conditions, for example drug-induced liver injury.

**FIGURE 1** Proposed immunopathogenic mechanisms in AIH and sites of action of experimental therapies. BAFF, B cell-activating factor of the tumour necrosis factor family; JAK, Janus kinase; PIF, pre-implantation factor; Treg, regulatory T cells.
Lack of efficacy or toxicity observed in trials for rheumatological disorders has led to the abandonment of several drugs targeting BAFF. Despite this, belimumab, a monoclonal anti-BAFF IgG1, has been FDA approved for the treatment of systemic lupus erythematosus based upon favourable trial outcomes. Blisibimod, a peptibody made by the fusion of a BAFF-binding peptide to IgG1Fc, has been demonstrated to improve fatigue in systemic lupus erythematosus, with an acceptable safety profile, although other clinical benefits were limited.

While no formal testing of targeting the BAFF pathway in AIH has been reported to date, a phase II multicentre, randomised, double-blind, placebo-controlled trial of an anti-BAFF receptor monoclonal antibody (VAY736, ianalumab) (Figure 2A) in patients with incomplete response or intolerance to current standard of care is underway (ClinicalTrials.gov: NCT03217422). Eighty adult patients with type 1 AIH and elevated alanine aminotransferase (ALT) (>1.5X upper limit of normal) and elevated IgG, despite (or intolerant of) adequate conventional first-line therapy will be randomised to one of four arms: placebo, ianalumab 5 mg every 4 weeks, 50 mg every 4 weeks or 300 mg every 4 weeks for 24 weeks, after which the placebo arm will be switched to 150 mg active drug until week 52. A second phase of the study aims to enrol 280 patients randomised 5:2 ianalumab:placebo for 52 weeks. The primary endpoint for both study phases is normalisation of ALT at 24 weeks with histological assessment at 24 (phase 1 only) and 52 weeks. The study is currently recruiting for phase 1.

Ianalumab has been trialled in primary Sjögren's syndrome in a phase II, placebo-controlled study of 27 patients, demonstrating a good safety profile, without observed hepatotoxicity or increased infection risk. An injection reaction with fever, headache, nausea and chills was common and may have been associated with higher circulating B cell frequencies at the time of treatment. Nonsignificant, dose-dependent trends towards improved clinical measures of disease activity and fatigue were observed. The phase 2b extension study of 190 patients has been reported in an abstract, which described significant improvements in disease activity and similar safety profile. Ongoing trials in chronic lymphocytic leukaemia (ClinicalTrials.gov: NCT03400176), systemic lupus erythematosus (ClinicalTrials.gov: NCT03656562) and rheumatoid arthritis (ClinicalTrials.gov: NCT02675803) will give further information regarding toxicity and tolerability. Advantages of ianalumab include monthly subcutaneous injection making concordance easier, with the potential for self-injection at home and modest delivery costs. A positive trial outcome would offer robust evidence for B cell targeting therapies in AIH and potentially a new third-line agent; the results of this trial are awaited with interest.

3.2 | Anti-tumour necrosis factor therapy

Tumour necrosis factors (TNFs) are cytokines produced by macrophages and effector T cells. TNFα activates the NFκB and MAPK
pathways via two receptors and complex signalling pathways, and can result in a range of proinflammatory responses (see Figure 2B), including cell apoptosis, proliferation or activation, that lead to necrosis and inflammation, depending upon which receptor is bound, and cross-talk with other signalling pathways. The role of TNFα in autoimmune disorders is well established and several pharmacological agents that inhibit the actions of TNF-α are available, including monoclonal antibodies (infliximab and adalimumab) and soluble TNF receptor-IgG fusion molecules (etanercept). These drugs have established roles in the management of autoimmune and inflammatory disorders including rheumatoid arthritis, inflammatory bowel disease and psoriatic arthritis.

TNFα is important in inflammatory liver disease and there is growing evidence implicating it in the pathogenesis of AIH. TNFα, IFNγ- and IL17-secreting T cells are believed to cause or co-ordinate hepatic damage; liver-infiltrating lymphocytes are enriched with populations of effector T cells that secrete these cytokines in AIH109,110 (Figure 1), and variants in the TNFα gene have been associated with AIH.111,112 Also, in a murine model of immunoinflammatory hepatitis induced by the plant lectin concanavalin A, TNFα was pivotal in the generation of liver injury. Therefore, with readily available drugs and evidence for a pathogenic role for TNFα, there has been growing interest in antagonism of TNFα to treat AIH.

Infliximab has been used as rescue therapy in patients with difficult-to-treat AIH; early experience demonstrated reduced inflammation; however, high rates of infectious complications were reported.112-114 However, a retrospective report of 11 paediatric cases with concomitant autoimmune liver disease (two with AIH and nine with autoimmune sclerosing cholangitis) treated with anti-TNF therapy for severe inflammatory bowel disease demonstrated stable or improved liver function tests and only a single infective complication of asymptomatic cytomegalovirus viraemia.115 There are concerns regarding idiosyncratic hepatotoxicity with anti-TNF therapy and the impact of this on patients with already impaired liver function needs to be carefully considered. In the largest series of 11 patients with AIH, some received infliximab following failure of first-line therapy with azathioprine or corticosteroids due to intolerance or inadequate response and a minority received it due to failure of second- and third-line therapies,112 suggesting that infliximab may have a role at many points in the treatment algorithm for AIH (Table 1). Additionally, there is interest in the use of infliximab for induction therapy in AIH, and this is being actively explored in some centres, such as in Hamburg, Germany.

In the published experience with infliximab, 5 mg/kg intravenous infusion of infliximab at weeks 0, 2, 6 and 10 with ongoing treatment administered at monthly intervals has been used.112 When used in inflammatory bowel disease, an immunomodulator is typically given concurrently to reduce the risk of the generation of anti-drug antibodies leading to reduced efficacy, and this should be considered in the setting of AIH. Due to the risk of infection with anti-TNF drugs, they should be avoided in the setting of active infection and used only in the setting of compensated liver disease. There are now a range of biosimilar drugs available and these should be equivalent substitutes for infliximab.

3.3 | Pre-implantation factor

Pre-implantation factor is a 15 amino acid peptide secreted by mammalian embryos prior to implantation in the uterus.116 It functions to maintain pregnancy via a plethora of downstream actions mediated by binding to various proteins including insulin-degrading enzyme, Kv1.3b potassium channels, protein disulphide isomerases and heat shock proteins.117,118

In addition to inducing alterations in the local endometrial tissues, direct trophic effects upon the foetus and neurodevelopmental and neuroprotective effects,119 pre-implantation factor also acts to modulate the maternal immune system, engendering maternal tolerance to the allogeneic embryo. This is achieved through pleiotropic mechanisms inducing changes in gene expression; including upregulation of IL1 receptor-associated kinase 1 binding protein and suppression of IL12-receptor subunit β2, FK506 binding protein and immunoglobulin G gene and changes in adhesion proteins and regulators of apoptosis.117 Pre-implantation factor binds monocytes, activated CD4 and CD8 T lymphocytes and B lymphocytes and inhibits lymphocyte proliferation119,120 (Figure 1). Furthermore, pre-implantation factor influences lymphocyte cytokine production, increasing the production of immunoregulatory IL10, reducing proinflammatory cytokines, including interferon gamma, and induces a shift towards a Th2 profile of CD4 T cells.119,120 Pre-implantation factor also reduces nitric oxide production by macrophages, thereby reducing oxidative stress, and increases the expression of T cell inhibitory molecule PD-L1 by monocytes121 (see Figure 2C). Taken together, these data illustrate that pre-implantation factor is likely to modulate systemic immune responses and enhance immune tolerance.

Due to its potential effects on immune tolerance, the impact of pre-implantation factor on allo- and autoimmune responses has been considered. Pre-implantation factor reduces alloimmune-mediated damage in animal models of graft-versus-host disease.121 Administration of pre-implantation factor is protective against death and paralysis in experimental autoimmune encephalitis (a model of immune-mediated demyelination)122,123 and is protective in models of immune-mediated diabetes mellitus124 and atherosclerosis.125

Pre-implantation factor was awarded FAST-TRACK status by the FDA, and a phase I placebo-controlled study of pre-implantation factor administration in 18 patients with AIH demonstrated minimal toxicity.126 Pre-implantation factor may now be taken forward to efficacy trials and represents a potential novel therapy for AIH, although a phase 2 trial was announced and then withdrawn as the manufacturer reported a change in the focus of drug development. The advantages of pre-implantation factor are that it is a naturally occurring peptide, with no evidence of anti-pre-implantation factor antibody formation in the phase I study. The required dosing interval
is currently unknown, although with a half-life of 91 minutes, frequent subcutaneous dosing may be required.

3.4 | Strategies to enhance regulatory T cell function

CD4 regulatory T cells (Tregs) are defined by the presence of the transcription factor forkhead box P3 (FoxP3)\textsuperscript{127} and constitutively express CD25 (IL2Ra) and cytotoxic T lymphocyte antigen 4. They are capable of suppressing effector T cell responses by a variety of mechanisms including inhibition of CD28 co-stimulation,\textsuperscript{126} sequestering IL2 via CD25 (thereby depriving effector T cells of this important stimulatory signal),\textsuperscript{129} generation of the immunoregulatory nucleoside adenosine,\textsuperscript{130} interleukin (IL) 10 and transforming growth factor-β secretion\textsuperscript{131} and direct cellular cytotoxicity.\textsuperscript{132,133}

Tregs are critical in the balance of self-tolerance and immune reactivity. Inability to produce functional Treg due to genetic deficiency of FoxP3 leads to immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome (IPEX) in humans and scurfy in mice, both of which are characterised by systemic autoimmunity and lymphoproliferation.\textsuperscript{134-137} Selective depletion of Treg in adult mice leads to a similar phenotype characterised by autoimmune hyper-reactivity,\textsuperscript{138} suggesting that Tregs have a pivotal role in both the generation and maintenance of self-tolerance.

Tregs have been developed as a therapeutic option in autoimmune conditions, with focus recently in AIH. Ex vivo expansion, stimulation and transfer of Treg and the administration of low-dose IL2 are two strategies actively being explored in AIH (Figures 1 and 2D).

3.4.1 | Adoptive transfer of Treg

Due to the importance of Treg in maintenance of self-tolerance, the frequency and function of Treg in AIH have been investigated. Data on the frequency of Treg in AIH are conflicting,\textsuperscript{65,66,139-141} but the expression of proteins important for suppressive function, such as FoxP3, cytotoxic T lymphocyte antigen 4 and IL10, is reduced\textsuperscript{65,66,139} and their suppressive activity may be impaired\textsuperscript{65-67} Intrahepatic Tregs are frequent at the time of diagnosis but decline with treatment\textsuperscript{142} and may become functionally impaired by an IL2 deficient, inflamed, liver microenvironment.\textsuperscript{74} These data suggest that there may be a deficit in Treg function in AIH but further work is required to comprehensively define this. Augmentation of Treg function represents a potential treatment strategy for AIH irrespective of whether a Treg defect is required for the genesis of the disease as enhanced Treg function may improve the control of aberrant autoimmune responses.

Adoptive Treg transfer has shown early promise in the control of autoimmune and alloimmune responses. Two independent phase I studies of autologous Treg therapy in type 1 diabetes have demonstrated an acceptable safety profile, the sustained persistence of transferred Treg and possible clinical improvements.\textsuperscript{143,144} Adoptive transfer of autologous, donor-specific Treg following living donor liver transplantation has been successful allowing 7/10 patients to be weaned off immunosuppression within 3 years of transplantation.\textsuperscript{145} Additionally, several studies have demonstrated efficacy for adoptive Treg therapy in graft-versus-host disease.\textsuperscript{146-148} Taken together, this body of work illustrates an acceptable safety profile and potential efficacy of adoptive Treg transfer in preventing autoimmune and alloimmune responses.

No trial assessing the efficacy of Treg therapy in autoimmune liver diseases has been undertaken to date. However, a study tracking the distribution of autologous Treg after infusion in patients with AIH demonstrated both the feasibility of autologous Treg generation from patients with AIH and the homing of infused Treg to the liver of four patients, suggesting that this therapeutic approach is a realistic proposition.\textsuperscript{149}

The advantages of this approach include the autologous nature of the cell product, which reduces the likelihood of immune responses against the therapeutic product, and the potential that Treg therapies may restore self-tolerance. However, questions relating to the durability of Treg themselves, their clinical effect, the potential for de-differentiation to nonregulatory effector T cells that could exacerbate inflammatory processes and the risk of malignancy and infection remain.\textsuperscript{150} Furthermore, this approach is costly, complex and difficult to administer compared to conventional pharmacological therapies.

3.4.2 | Low-dose IL2 therapy

Low-dose IL2 therapy is under active investigation as a treatment strategy for a variety of autoimmune disorders. IL2 is a critical survival factor for T cells and important for their proliferation. Treatment with low-dose IL2 exploits the greater IL2 sensitivity of Treg, compared to other effector T cells,\textsuperscript{151} to shift the balance of immune responses in favour of regulation.

Low-dose IL2 treatment increases Treg number and activity, without significant activation of other effector T cells or toxicity in a range of conditions including hepatitis C virus-induced vasculitis,\textsuperscript{152} graft-versus-host disease,\textsuperscript{153} type 1 diabetes,\textsuperscript{154} alopecia areata\textsuperscript{155} and systemic lupus erythematosus.\textsuperscript{156,157}

Evidence for a specific role for IL2 in the pathogenesis of AIH is limited. Serum IL2 is higher in paediatric patients with AIH at disease onset compared to following treatment and similarly a reduction in intrahepatic Treg frequency is noted during treatment.\textsuperscript{158} However, a study of adult AIH patients showed no differences in serum IL2 levels.\textsuperscript{159} Treg from patients with AIH do appear to have defective responses to IL2, with a failure to increase production of the immunoregulatory cytokine IL10 after IL2 treatment.\textsuperscript{65} Treg from patients with AIH may recover function following treatment with IL2. In vitro low-dose IL2 treatment of hepatic or peripheral blood lymphocytes of patients with autoimune liver diseases leads to Treg-specific expression of effector proteins, without the loss of liver homing chemokine receptors.\textsuperscript{160}
Low-dose IL2 treatment has been reported in patients with AIH. Two patients with type 1 AIH who had inadequate response to conventional second-line immunosuppressive therapy received \(1 \times 10^6\) IU IL2 subcutaneously for five consecutive days a month leading to short-term expansion of the circulating Treg compartment with no adverse events.\(^{161}\) A further two patients with AIH were included in an open-label trial of low-dose IL2 in a cohort of patients with a range of autoimmune disorders, again illustrating that the treatment was well tolerated and resulted in increased circulating Treg.\(^{162}\) These studies pave the way for the formal assessment of low-dose IL2 in AIH.

Modified versions of IL2 are being developed to improve Treg selectivity and longevity. Mutated forms of IL2 that selectively bind the trimeric, high-affinity receptor IL2 rather than the low-affinity dimeric receptor will hopefully enhance Treg selectivity and reduce conventional T cell activation, thereby further skewing immune responses towards regulation. Conjugation of IL2 to other moieties with the aim of prolonging its plasma half-life is also under investigation.\(^{163}\)

### 3.4.3 Treg stimulators

In addition to the administration of ex vivo expanded Treg and low-dose IL2 to increase Treg numbers, enhancement of Treg differentiation and stimulation through the use of tolerogenic dendritic cells and mesenchymal stem cells\(^{164}\) are being actively explored.

T cell stimulation requires engagement of the T cell receptor with its cognate antigen presented by an antigen-presenting cell alongside a co-stimulation signal. Dendritic cells act as antigen-presenting cells and, depending upon the cytokines and other signals such as damage and pathogen-associated molecular patterns present when they are exposed to antigen, can acquire a tolerogenic or proinflammatory phenotype. Tolerogenic dendritic cells maintain Treg populations and can divert naïve conventional T cells to become Treg\(^{165}\) or induce anergy in reactive conventional T cells,\(^{166}\) hence autologous tolerogenic dendritic cells have been tested in autoimmune conditions to change the balance between endogenous Treg and conventional T cell responses in favour of tolerance. In phase I studies, autologous, ex vivo expanded tolerogenic dendritic cells have been administered to patients with type 1 diabetes,\(^{167}\) rheumatoid arthritis\(^{168,169}\) and inflammatory bowel disease.\(^{170}\) As well as acceptable safety profiles and feasibility, increased frequencies of circulating Treg, impaired Th1-type T cell responses and reduced circulating effector T cell frequency have been observed,\(^{166,170}\) suggesting appropriate support for a regulatory T cell response can be achieved. Thus, it appears possible that endogenous Treg responses can be stimulated in vivo by the use of autologous cell therapies, although robust evidence of efficacy is awaited.

The development of and increasing experience with Treg therapies, low-dose IL2 technology and dendritic cell therapies mean that these have become realistic experimental possibilities for the treatment of AIH in the coming years. Targeting the Treg axis represents an attractive approach in AIH as it may offer immunoregulation without immunosuppression and correct a pathway known to be dysfunctional with minimal toxicity.

### 4 POTENTIAL FUTURE THERAPEUTIC TARGETS IN AIH

The pivotal role of IL1, IL6 and that JAK signalling molecules in autoimmune responses has led to the development of therapies to specifically target these pathways. Here, we discuss below the evidence for these as targets in AIH and consider the potential for testing the efficacy of these in the future.

#### 4.1 Anti-interleukin 1 and anti-interleukin 6 therapy

IL1 and IL6 are proinflammatory cytokines and antagonism of their function may be of benefit in autoimmunity (Figure 2E). IL1α is a cytoplasmic and cell surface molecule that is released following cell death, whereas IL1β is actively secreted. Both molecules bind the IL1 receptor (IL1R1), which is expressed on all nucleated cells, but this interaction is competitively inhibited by the binding of IL1 receptor antagonist (IL1Ra) to IL1R1 or by binding of the cytokine to the nonsignalling decoy receptor IL1R2.\(^{271}\) IL1 has pleiotropic effects upon the neurological, cardiovascular and hormonal systems and upon electrolytes and extracellular matrix turnover.\(^{271}\) Within the immune system, it induces acute phase protein production and recruits neutrophils and macrophages to sites of tissue damage or infection.\(^{272}\) IL1 also stimulates T cells resulting in the differentiation of Th17 cells\(^{273}\) that are known to be important in many autoimmune disorders.

IL6 is produced by a broad range of cells, including most immune and stromal cells.\(^{274}\) The regulation of IL6 expression is complex and influenced by many signals including cytokines, such as IL1 and TNFs, bacterial and viral products and several well-described signalling pathways.\(^{274,275}\) IL6 has a broad spectrum of actions within the immune system, regulating innate and adaptive responses. It is important in regulating the production of acute phase proteins\(^{276}\) and the migration of neutrophils to the site of inflammation.\(^{274}\) IL6 promotes the survival and expansion of T cells\(^{277}\) and induces CD4 T follicular helper cell differentiation,\(^{278}\) plasma cell formation and antibody production,\(^{279}\) both directly and indirectly, via T follicular helper cells. IL6 also induces the survival and proliferation of Th1 and Th2 CD4 cells and its presence prevents transforming growth factor-β-mediated differentiation of CD4+ Foxp3+ inducible Treg, instead resulting in the differentiation of Th17 cells.\(^{69}\)

Due to the pivotal roles for IL1 and IL6 in inflammation, evidence for their association with autoimmune disorders and liver inflammation has been sought. IL1 production is elevated in
patients with fulminant hepatic failure and alcoholic hepatitis, and elevated IL1β:IL1RA ratio is observed in severe hepatitis C virus-associated inflammation. However, elevated IL1 levels have not been convincingly demonstrated in AIH, and AIH is not associated with gene variants in IL1β or IL1Rα. Some evidence suggests that IL6 may be altered in AIH. However, while elevated serum levels of IL6 have been reported to be associated with AIH, and fall during remission, IL6 levels do not correlate with disease activity and the association is lost after adjustment for other cytokines and clinical parameters. Additionally, in another patient cohort, the vast majority of patients had undetectable serum IL6 levels despite active disease. In vitro stimulation of peripheral blood mononuclear cells from patients with AIH demonstrated a greater capacity for the production of IL6 among others in patients with AIH compared to healthy controls or those with hepatitis B infection.

Ultimately, irrespective of whether variation in IL1 or IL6 are important in the genesis of AIH, they are key mediators of inflammation hence antagonism of these pathways may help in the resolution of hepatitis.

Therapeutic blockade of the IL1 axis has been successful in several conditions and a range of agents are available. These include anakinra (a recombinant, modified analogue of IL1Ra) that competitively inhibits IL1 binding to IL1R1, rilonacept (a soluble form of IL1R) and canakinumab (a neutralising monoclonal antibody against IL1β). Anakinra has moderate benefit in the treatment of rheumatoid arthritis and psoriatic arthritis and may be of use in systemic lupus erythematosus, ankylosing spondylitis and type 1 diabetes. Although randomised controlled clinical trial data have been disappointing. Additionally, a range of inflammatory disorders can also be controlled with IL1 antagonism and there is a multicentre, placebo-controlled phase 2 trial of canakinumab in moderate acute alcoholic hepatitis underway in the United Kingdom (ClinicalTrials.gov: NCT03775109).

The IL6 pathway has been targeted in several conditions. Tocilizumab is a humanised monoclonal against the IL6 receptor and has been approved for use in rheumatoid arthritis following a range of positive trial outcomes including in patients refractory to anti-TNF therapies. Tocilizumab is also efficacious for the treatment of systemic lupus erythematosus, juvenile idiopathic arthritis and giant-cell arteritis, although other agents targeting the IL6 pathway in systemic lupus erythematosus have been less successful. Studies targeting the IL6 pathway in a range of other inflammatory conditions have also been completed.

The toxicity of agents antagonising the IL1 and IL6 pathways has been extensively assessed and hepatotoxicity, defined as elevated transaminases, has been reported with IL6 antagonism but not IL1. As IL6 is an important mitogen for hepatocytes and is important in liver regeneration, careful timing of IL6 antagonism would be needed to avoid disturbing native liver repair mechanisms. Both IL1 and IL6 antagonism are associated with increased risks of infection and suppression of leucocyte counts. However, these observations need to be considered in relation to the adverse events, including hepatotoxicity and infection, associated with currently used therapies in AIH.

The availability of agents that inhibit these key proinflammatory cytokines, with associated acceptable safety profiles, offers the option for clinical trials in AIH and should be actively considered. Initial review of existing trial data may illustrate whether any patients with AIH have been treated for other indications, and controlled clinical trialling in AIH seems appropriate.

4.2 Janus Kinase inhibitors

Janus Kinases (JAKs), comprising of JAKs 1-3 and tyrosine kinase 2, are intracellular kinases that are integral to the signalling pathways for many cytokines. After a cytokine binds to its cognate receptor, receptor-specific JAKs are activated and phosphorylate themselves and the intracellular tail of the receptor. This enables receptor signalling, ultimately leading to the activation of specific members of the STAT family of transcription factors (Figure 2F). JAK expression is cell specific and the association of particular cytokine receptors and JAKs is specific, which may allow targeting of each JAK to modulate narrow ranges of cytokine signals.

JAKs are important in inflammatory responses and haematopoiesis and therefore attention has been focused on the inhibition of JAK signalling to limit inflammatory responses in autoimmune and inflammatory disorders. Nonselective first-generation JAK inhibitors are small molecule enzyme inhibitors that block the function of all JAKs (eg tofacitinib and peficitinib) or JAK1 and 2 alone (ruxolitinib and baricitinib). Efficacy has been demonstrated for tofacitinib in the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, although results in Crohn’s disease have been disappointing. Ruxolitinib may reduce symptoms in rheumatoid arthritis and is effective topically for psoriasis.

A range of second-generation JAK inhibitors, which selectively target JAK1 and/or JAK3, remain at early trial stages but efficacy of filgotinib in rheumatoid arthritis and Crohn’s disease has been reported. Problems with leucopenia are encountered with these drugs and their relative sparing of JAK2 prevents blockade of the important proinflammatory Th1 cytokines IL12 and IL23.

JAK inhibitors represent a potential treatment for AIH as they have the potential to target cytokine producing and responsive lymphocytes that are important in liver autoimmunity. Furthermore, the association of variants in Src Homology 2 adaptor protein 3 (SH2B3/Lnk) with AIH in genomic studies and evidence for mutations in SH2B3 driving JAK-STAT signalling make inhibition of JAKs an attractive target.

Other appealing features of these drugs are their rapid onset of action and oral route of administration. However, the lack of long-term safety data, the observations of transaminitis and myelosuppression and a concern about long-term cancer risks represent challenges to their use at present. While there is growing evidence that JAK inhibitors may be useful in the management of a range of
autoimmune disorders, and they offer an intellectually attractive approach to managing inflammation in AIH, there has been no formal testing to date.

5 | EXPERIMENTAL APPROACH IN AIH

There are many novel treatment approaches that may be applicable to AIH in the coming years and with active trials open for anti-BAFF receptor and anti-TNF agents in AIH, new treatment options are a realistic proposition. Additionally, pharmacological agents targeting IL1, IL6, BAFF and JAKs are on the market and large trial databases exist that should be analysed to identify patients with AIH who were treated for other indications to determine signals of toxicity or clinical benefit in AIH. This approach could inform which drugs could next go forward into clinical trialling.

Experimental therapies, including pre-implantation factor, Treg therapy and low-dose IL2, are nearing the point where formal clinical trials are being established, and these treatments may be available in trial settings over the coming years.

There remains a need for new treatment approaches in AIH and as our understanding of the dosing, monitoring and toxicity of these new drugs become established, the barriers to establishing trials of these new agents are reduced. Novel and experimental therapies should be offered in specialist units with expertise in the management of AIH, experience in the delivery of therapeutic drug trials and wherever possible under the auspices of formal prospective clinical trials.

The positioning of novel treatments in the management of AIH is not straightforward. Currently, the approach of induction and maintenance of remission with corticosteroids and azathioprine with the aim of corticosteroid-free remission on azathioprine monotherapy has a strong evidence base. Despite this, a significant proportion of patients do not achieve corticosteroid-free remission, experience a significant burden of side effects and have high rates of relapse both on treatment and following cessation of therapy. In patients with preserved hepatic synthetic function and without evidence of advanced liver disease, it may be acceptable to conduct non-inferiority studies comparing newer agents against corticosteroids for the induction of remission, especially once evidence of efficacy is observed in nonresponders, as delay in remission is unlikely to be associated with adverse outcomes. For patients with an intolerance of, or inadequate response to, conventional first-line therapy for the maintenance of remission, randomised controlled trials of novel agents should be offered. Ianalumab is currently available in a placebo-controlled randomised trial in this setting.

Assessment of new agents following the failure of second- or third-line treatments has the potential for poor outcomes; this group of patients have ‘difficult-to-treat’ disease by definition and may be more resistant to treatment meaning that the efficacy of novel agents may be underestimated. Furthermore, several trials have been limited by poor recruitment due to the difficulties in identifying suitable candidates for enrolment. Thus, there is the potential to significantly delay the introduction of novel therapies for the treatment of AIH. Therefore, trial designs for novel therapeutics should consider their introduction at the point of failure of first-line treatments, as well as after second- or third-line failures, and consideration should be given to studies assessing new drugs for non-inferiority against first-line treatments in patients with low-risk disease.

6 | CONCLUDING REMARKS

There is an unmet clinical need in AIH for new therapeutic agents due to intolerance of, or inadequate response to, conventional agents, and the significant side effect burden experienced by patients. Robust evidence for currently used second- and third-line agents remains lacking and the pharmacological agents available to treat AIH have not been expanded for many years. Due to advances in our understanding of the pathophysiology of AIH and autoimmunity more broadly, several novel agents are in development or have an established role in other autoimmune disorders, which may be of use in the management of AIH. The challenge now facing the field is the funding and design of effective clinical trials that will allow the establishment of these novel agents as third-line, or potentially earlier, agents in AIH. There is an exciting wealth of experimental therapies in development and this, combined with the collaborative, international approach to the investigation and management of AIH, will hopefully encourage investment from industry to drive the development of novel therapeutics for this rare but important disease.

ACKNOWLEDGEMENTS

All authors of this publication are members of the European Reference Network for Rare Liver Diseases (ERN-RARE LIVER) Project ID No 739543.

Declaration of personal interests: Ansgar Lohse has served as a consultant for Genfit and Roche. All other authors declare no personal interests.

FUNDING INFORMATION

No specific funding was applied for, nor received, for the writing of this article.

AUTHORSHIP

Guarantor of the article: NH.

Author contributions: All authors determined the concept and scope of the article. NH and JKD undertook literature searching and wrote the article. All authors reviewed and edited the manuscript and approved the final version of the article.

ORCID

Neil Halliday https://orcid.org/0000-0001-8220-9139
Jessica Katharine Dyson https://orcid.org/0000-0001-6733-5225
REFERENCES

1. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.

2. de Boer YS, van Gerven NMF, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147:443-452.e5.

3. Hennes EM, Zeniya M, Aj, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176.

4. Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev. 2014;13:435-440.

5. Webb GJ, Hirschfield GM. Genetics of autoimmune liver disease: a brief summary for clinicians. Dig Dis. 2014;32:e1-e6.

6. Yeoman AD, Westbrook RH, Zenewicz LA, Abraham C, Flavell RA, Cho JH. Unraveling the genetics of autoimmunity. Nat Rev Genet. 2010;11:198-209.

7. Lessard CJ, Ice JA, Adrianto I, et al. The genomics of autoimmune diseases. Phil Trans R Soc B. 2014;369:20130365.

8. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1999;340:1992-1999.

9. van den Brand FF, van de Veen KS, Lissenberg-Witte BI, et al. Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther. 2010;31:1020-1029.

10. H peninsula A, Chalopin J, Raknerud N, Strøm M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99-103.

11. Hurlbut R, McMahan BJ, Deubner H, Hsu-Trawinski B, Williams JL, Rowley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402-2407.

12. Ng JH, Bchly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010;25:1681-1686.

13. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675-688.

14. Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med. 2016;164:724-732.

15. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971-1004.

16. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1999;340:1992-1999.

17. van den Brand FF, van de Veen KS, Lissenberg-Witte BI, et al. Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther. 2010;31:1020-1029.

18. Wodtke ML, Fisher HF, Stocken DD, et al. Diagnosis of autoimmune hepatitis in adult and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Aliment Pharmacol Ther. 2020;52:761-767.

19. Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723-732.

20. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a cohort of treatment-naive patients. J Hepatol. 2011;55:636-646.

21. Hlivo JT, Shiffman ML, Stratvis RJ, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036-1040.

22. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063-3070.

23. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588-592.

24. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156-160.

25. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371-375.

26. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to or intolerant of standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2004;18:321-326.

27. Pradhan S, Garg A, Venkatesh S, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723-727.

28. Inducutio-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799-802.

29. Wolf DC, Bojito L, Faciutti M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519-2522.

30. Efe C, Hagerström H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15:1950-1956.
12. The first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther.* 2016;43:1035-1047.

41. Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis—an observational study. *J Clin Exp Hepatol.* 2014;4:221-225.

42. Baven-Pronk AMC, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. *Aliment Pharmacol Ther.* 2011;34:335-343.

43. Czaja AJ. Current and future treatments of autoimmune hepatitis. *Expert Rev Gastroenterol Hepatol.* 2009;3:269-291.

44. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. *Liver Int.* 2005;25:734-739.

45. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. *Gastroenterology.* 1997;112:2028-2035.

46. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. *Hepatology.* 1994;19:609-615.

47. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. *Hepatology.* 1997;25:317-323.

48. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. *Hepatology.* 2000;31:49-53.

49. Djilali-Saia I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD 28 region polymorphisms in children with families with autoimmune hepatitis. *Hum Immunol.* 2001;62:1356-1362.

50. Eskandari-Nasab E, Tahmasebi A, Hashemi M. Meta-analysis: the relationship between CTLA-4 +49 A/G polymorphism and primary biliary cirrhosis and type I autoimmune hepatitis. *Immunol Invest.* 2015;44:331-348.

51. Migita K, Nakamura M, Abiru S, et al. Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population. *PLoS One.* 2013;8:e71382.

52. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. *Tissue Antigens.* 2007;69:227-235.

53. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis. *Hepatology.* 2002;35:126-131.

54. Fan L, Tu X, Zhu YE, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. *J Gastroenterol Hepatol.* 2005;20:249-255.

55. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type I autoimmune hepatitis. *Hepatology.* 1999;30:851-856.

56. Qin B, Li J, Liang Y, Yang Z, Zhong R. The association between Cytotoxic T lymphocyte associated antigen-4, Fas, tumour necrosis factor-alpha gene polymorphisms and autoimmune hepatitis: a meta-analysis. *Dig Liver Dis.* 2014;46:541-548.

57. Paladino N, Flores AC, Fairbairn H, et al. The most severe forms of type 1 autoimmune hepatitis are associated with genetically determined levels of TGF-beta1. *Clin Immunol.* 2010;134:305-312.

58. Webb GJ, Hirschfield GM, Krawitt EL, Gershwin ME. Cellular and molecular mechanisms of autoimmune hepatitis. *Annu Rev Pathol.* 2018;13:247-292.

59. Floreni T, Restrepo-Jiménez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis. *J Autoimmun.* 2018;95:133-143.

60. Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. *J Autoimmun.* 2016;66:60-75.

61. Böttcher K, Romboots K, Saffioti F, et al. MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. *Hepatology.* 2018;68:172-186.

62. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol.* 1995;155:1151-1164.

63. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. *Nat Immunol.* 2002;3:944-950.

64. Liberal R, Grant CR, Longhi MS, et al. Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease. *IJUBM Life.* 2015;67:88-97.

65. Liberal R, Grant CR, Holder BS, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. *Hepatology.* 2015;62:863-875.

66. Ferrì S, Longhi MS, De Molo C, et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. *Hepatology.* 2010;52:999-1007.

67. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. *J Autoimmun.* 2005;25:63-71.

68. Sakkas Li, Daoussis D, Mavropoulos A, Liosis S-N, Bogdanos DP. Regulatory B cells: new players in inflammatory and autoimmune rheumatic diseases. *Semin Arthritis Rheum.* 2019;48:1133-1141.

69. Bettielli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature.* 2006;441:235-238.

70. Liu Y, Yan W, Yuan W, et al. Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis. *Clin Immunol.* 2019;198:79-88.

71. Liang M, Liwen Z, Yun Z, Yando D, Jianping C. The Imbalance of IL-10 and IL-23 in Patients with Newly Diagnosed Autoimmune Hepatitis. *J Imm Res.* 2018;2018:3753081.

72. Zhao Li, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. *PLoS One.* 2011;6:e18909.

73. Lafidil F, Wang H, Park O, et al. Myeloid STAT3 inhibits T helper 1 cytokine and interleukin-17 production. *Gastroenterology.* 2009;137:2125-2135.e1-2.

74. Chen Y-Y, Jeffery HC, Hunter S, et al. Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. *Hepatology.* 2016;64:138-150.

75. Tiniakos DG, Brain JR, Bury YA. Role of histopathology in autoimmune hepatitis. *Dig Dis.* 2015;33:53-64.

76. Chan OTM, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. *J Exp Med.* 1999;189:1639-1648.

77. Burak KW, Swain MG, Santodomingo-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. *Can J Gastroenterol.* 2013;27:273-280.

78. Rubin JN, Te HS. Refractory autoimmune hepatitis: beyond standard therapy. *Dig Dis Sci.* 2016;61:1757-1762.

79. Al-Busafi SA, Michel RP, Deschenes M. Rituximab for refractory autoimmune hepatitis: a case report. *Arab J Gastroenterol.* 2013;14:135-138.

80. Than NN, Hodson J, Schmidt-Martin D, et al. Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results
from the International Autoimmune Hepatitis Group. *JHEP Rep*. 2019;1:437-445.
81. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. *Nat Rev Immunol*. 2002;2:465-475.
82. Migita K, Abiru S, Maeda Y, et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. *Hum Immunol*. 2007;68:586-591.
83. Nishikawa H, Enomoto H, Iwata Y, et al. B-Cell activating factor belonging to the tumor necrosis factor family and interferon-γ-inducible protein-10 in autoimmune hepatitis. *Medicine*. 2016;95:e3194.
84. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. *Arthritis Rheum*. 2001;44:1313-1319.
85. Migita K, Ilyassova B, Kovzel EF, et al. Serum BAFF and APRIL levels in patients with PBC. *Clin Immunol*. 2010;134:217-225.
86. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. *J Immunol*. 2001;166:6-10.
87. Petri M, Stohl W, Chatham W, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. *J Clin Immunol*. 2005;25:189-201.
88. Fabris M, Visentini D, De re V, et al. Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. *Scand J Gastroenterol*. 2007;42:1434-1439.
89. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. *J Clin Immunol*. 2005;25:189-201.
90. Deng F, Chen J, Zheng J, et al. Association of BAFF and IL-17A with subphenotypes of primary Sjögren’s syndrome. *Int J Rheum Dis*. 2016;19:715-720.
91. Maslinska M, Kontny E, Kwiatkowska B. The relationship between the presence of autoantibodies, indicators of local and systemic inflammation, the serum concentration of B-cell activating factor (BAFF) and the intensity of salivary gland infiltration in patients with primary Sjögren’s syndrome - a preliminary study. *Reumatologia*. 2015;53:321-327.
92. Matsushita T, Hasegawa M, Yanaka B, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. *Arthritis Rheum*. 2006;54:192-201.
93. Raghesh S, Lisak R, Lewis R, Van Stavern G, Gonzales F, Simon K. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. *Arch Neurol*. 2008;65:1358-1362.
94. Kang SY, Kang CH, Lee KH. B-cell-activating factor is elevated in serum of patients with myasthenia gravis. *Muscle Nerve*. 2016;54:1030-1033.
95. Pers J-O, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. *Ann N Y Acad Sci*. 2005;1050:34-39.
96. Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): A narrative review. *Scand J Immunol*. 2011;73:1-7.
97. Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leukocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. *Clin Exp Immunol*. 2015;180:40-51.
98. Lazaro E, Scherlinder M, Truchetet M-E, et al. Biotherapies in systemic lupus erythematosus: new targets. *Joint Bone Spine*. 2017;84:267-274.
99. Liget K, Sallaberry C, Hsu H, et al. Novel modalities of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. *Clin Exp Rheumatol*. 2012;30:197-201.
100. Dorner T, Posch MG, Li Y, et al. Treatment of primary Sjögren’s syndrome with analumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. *Ann Rheum Dis*. 2019;78:641-647.
101. Smolen J, Nash P, Tahir H, et al. Analumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, for treatment of primary Sjögren’s syndrome: results of an international randomized, placebo controlled dose range finding study in 190 patients [abstract]. *Arthritis Rheum*. 2019;71. https://acrabstracts.org/abstract/analumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/. Accessed July 20, 2020.
102. Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. *Cytokine Growth Factor Rev*. 2014;25:453-472.
103. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. *QJM*. 2010;103:917-928.
104. Bovensiepen CS, Schakat M, Sebode M, et al. TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis. *J Immunol*. 2019;203:3148-3156.
105. Oo YH, Banz V, Kavanagh D, et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. *J Hepatol*. 2012;57:1044-1051.
106. Gantner F, et al. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. *Hepatology*. 1995;21:190-198.
107. Wellner-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. *J Hepatol*. 2013;58:529-534.
108. Rajanayagam J, Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. *J Hepatol*. 2013;59:908-909.
109. Weiler-Normann C, Wiegard C, Schramm C, Lohe AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. *Am J Gastroenterol*. 2009;104:2877-2878.
110. Nedelkopolou N, Vadamalayan B, Vergani D, Mielli-Vergani G. Anti-TNFα treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease. *J Pediatr Gastroenterol Nutr*. 2018;66:100-105.
111. Barnea ER, Almogi-Hazan O, Or R, et al. Immune regulatory and neuroprotective properties of preimplantation factor: from newborn to adult. *Pharmacol Ther*. 2015;156:10-25.
112. Paidas MJ, Krikun G, Huang SJ, et al. A genomic and proteomic investigation of the impact of preimplantation factor on human decidual cells. *Am J Obstet Gynecol*. 2010;202:459.e1-459.e8.
Barnea ER, Lubman DM, Liu YH, et al. Insight into preimplantation factor (PIF*) mechanism for embryo protection and development: target oxidative stress and protein misfolding (PDI and HSP) through essential RIKP [corrected] binding site. PLoS One. 2014;9:e100263.

Barnea ER, Kirk D, Ramu S, Roussey R, Paidas MJ. Preimplantation factor (PIF*) orchestrates systemic antiinflammatory response by immune cells: effect on peripheral blood mononuclear cells. Am J Obstet Gynecol. 2012;207:313.e1-313.e11.

Barnea ER, Kirk D, Todorova K, McElhinney J, Hayrabedyan S, Fernández N. PIF direct immune regulation: blocks mitogen-activated PBMCs proliferation, promotes TH2/TH1 bias, independent of Ca(2+). Immunobiology. 2015;220:865-875.

Azar Y, Shainer R, Almogi-Hazan O, et al. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model). Biol Blood Marrow Transplant. 2013;19:519-528.

Weiss L, Or R, Jones RC, et al. Preimplantation factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J Neuro Sci. 2012;312:146-157.

Migliara G, Mueller M, Piermattei A, et al. PIF* promotes brain development: target oxidative stress and protein misfolding (PDI and unfoldase) through essential RIKP [corrected] binding site.

Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell function:信念 oxidative stress and protein misfolding (PDI and unfoldase) through essential RIKP [corrected] binding site.

Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of Preimplantation factor (PIF) selects type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice. Endocrine. 2011;40:41-54.

Chih Chen Y, Rivera J, Fitzgerald M, et al. Preimplantation factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J Neuro Sci. 2012;312:146-157.

O'Brien CB, Barnea ER, Martin P, et al. Randomized, double-blind, placebo-controlled, single ascending dose trial of synthetic preimplantation factor in autoimmune hepatitis. Hepatol Commun. 2018;2:1235-1246.

Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.

Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600-603.

Pandian P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8:1353-1362.

Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2019;15:355-367.

Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523-532.

Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174:1783-1786.

Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opin Ther Targets. 2015;19:1091-1103.

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.

Khattri R, Cox T, Yasaakyo S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337-342.

Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18-20.
patients with systemic lupus erythematosus. *Ann Rheum Dis.* 2016;75:1407-1415.

157. He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+)-T cell subsets in patients with systemic lupus erythematosus. *Nat Med.* 2016;22:991-993.

158. Diestelhorst J, Junge N, Schlie J, et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. *PLoS One.* 2017;12:e0181107.

159. Akberova D, Kiassov AP, Abdulganieva D. Serum cytokine levels and their relation to clinical features in patients with autoimmune liver diseases. *J Immunol Res.* 2017:2017-9829436.

160. Jeffery HC, Jeffery LE, Lutz P, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. *Clin Exp Immunol.* 2017;188:394-411.

161. Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A. Low-dose interleukin-2 for refractory autoimmune hepatitis. *Hepatology.* 2018;68:1649-1652.

162. Rosenzweig M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. *Ann Rheum Dis.* 2019;78:209-217.

163. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. *Clin Exp Immunol.* 1999;115:515-520.

164. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. *Nat Immunol.* 2015;16:550-558.

165. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. *Int Immunol.* 2007;19:1613-1626.

166. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell immunity. *Immunity.* 2017;46:539-553.

167. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Natural killer cells are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol.* 2007;8:942-949.

168. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.* 2015;16:448-457.

169. Ataie-Kachoei P, Pourgholami MH, Richardson DR, Morris DL. Gene of the month: Interleukin-6 (IL-6). *J Clin Pathol.* 2014;67:932-937.

170. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. *Arthritis Res Ther.* 2006;8:52.

171. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. *J Immunol.* 1997;158:5791-5796.

172. Dienz Q, Eaton SM, Bonf JD, et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. *J Exp Med.* 2009;206:69-78.

173. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. *J Exp Med.* 1998;167:332-344.

174. Muto Y, Meager A, Nouri-Aria KT, et al. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. *Lancet.* 1988;332:72-74.

175. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. *Hepatology.* 1991;13:267-276.

176. Gramantieri L, Casali A, Trede E, et al. Imbalance of IL-1β and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. *Clin Exp Immunol.* 1999;115:515-520.

177. Fan LY, Tu XQ, Zhu Y, et al. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. *World J Gastroenterol.* 2005;11:2768-2772.

178. Thomas-Dupont P, Remes-Troche JM, Izaguirre-Hernández IY, et al. Elevated circulating levels of IL-21 and IL-22 define a cytokine signature profile in type 2 autoimmune hepatitis patients. *Ann Hepatol.* 2016;15:550-558.

179. Maggiore G, De FB, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. *J Pediatr Gastroenterol Nutr.* 1995;20:23-27.

180. Kamijo A, Yoshizawa K, Joshi S, et al. Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients. *Hepatol Res.* 2011;41:350-357.

181. Alwabel A, Aljanadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic hepatitis. *J Allergy Clin Immunol.* 1993;92:902-908.

182. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. *J Rheumatol.* 2009;36:1118-1125.

183. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). *Clin Rheumatol.* 2010;29:1169-1173.

184. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. *Ann Rheum Dis.* 2005;64:630-633.

185. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis.* 2005;64:296-298.

186. Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. *Pediatr Diabetes.* 2011;12:656-667.

187. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. *Lancet.* 2013;381:1905-1915.

188. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nat Rev Drug Discov.* 2012;11:633-652.

189. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet.* 2008;371:987-997.

190. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis.* 2008;67:1516-1523.
197. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. *Arthritis Rheum*. 2010;62:542-552.

198. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet*. 2008;371:1009-1006.

199. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med*. 2017;377:317-328.

200. Paley MA, Strand V, Kim AH. From mechanism to therapies in systemic lupus erythematosus. *Curr Opin Rheumatol*. 2017;29:178-186.

201. Iannone F, Ferraccioli G, Sinigaglia L, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. *Clin Rheumatol*. 2018;37:315-321.

202. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119-1131.

203. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. *J Hepatol*. 2016;64:1403-1415.

204. Gadina M, Gazaniga N, Vian L, Furumoto Y. Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases. *J Autoimmun*. 2017;85:20-31.

205. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? *Ann Rheum Dis*. 2018;77:175-187.

206. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*. 2014;370:2377-2386.

207. Singh JA, Hossain A, Tanjong Ghogomu E, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. *Cochrane Database Syst Rev*. 2017:CD012591.

208. Wang TS, Tsi T. Tofacitinib in psoriatic arthritis. *Immunotherapy*. 2017;9:1153-1163.

209. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2017;376:1723-1736.

210. Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIIb randomised placebo-controlled trials. *Gut*. 2017;66:1049-1059.

211. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. *Clin Gastroenterol Hepatol*. 2014;12:1485-1493.e2.

212. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. *J Am Acad Dermatol*. 2012;67:658-664.

213. Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/ GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). *Ann Rheum Dis*. 2017;76:998-1008.

214. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. *Lancet*. 2017;389:266-275.

215. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. *Blood*. 2010;116:988-992.

216. Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. *J Clin Transl Hepatol*. 2015;3:42-52.

217. Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis. *BioDrugs*. 2016;30:407-419.

218. Hartl J, Ehlen H, Weiler-Normann C, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. *J Hepatol*. 2015;62:642-646.

---

**How to cite this article:** Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. *Aliment Pharmacol Ther*. 2020;00:1-16. [https://doi.org/10.1111//apt.16035](https://doi.org/10.1111/apt.16035)